The potential of meropenem and piperacillin-tazobactam combination to Acinetobacter spp clinical isolates in vitro

https://doi.org/10.19106/JMedSci005201202001

Alindya Diani(1*), Eggi Arguni(2), Ludhang Pradipta Rizki(3)

(1) Undergraduate Program in Medicine, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta Indonesia
(2) Department of Pediatric, Dr. Sardjito General Hospital, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta Indonesia
(3) Department of Microbiology, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta Indonesia
(*) Corresponding Author

Abstract


Acinetobacter spp is one of the most common causes of nosocomial infection, especiallysepsis. A lot of antibiotics resistance happen related to Acinetobacter-related sepsis treatment. This study aimed to evaluate the potential of meropenem and piperacillin-tazobactam combination against Acinetobacter spp in in vitro by using paper strip test. This was experimental study conducted in September to December 2015 at Departement of Microbiology, Faculty of Medicine, Public health, and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia. Clinical isolates of Acinetobacter samples were obtained from collections of the Department of Microbiology. The data were analyzed using post-test analysis which was conducted by observation over 24 h after the paper strip test was applied in bacterial culture. The MIC value of the antibiotic combination was recorded based on observation. The result showed 12 of 17 clinical isolates were synergistic potential (70.59%) and 5 others were indifferent potential (29.41%). Two of five clinical isolates that show indifferent potential were A. baumannii and all of the clinical isolates that show synergistic potential were Acinetobacter spp. It can be concluded that the combination of meropenem and piperacillin-tazobactam showed more synergistic dominantly than the single use of each of them.


Keywords


sepsis; acinetobacter spp; paper strip test; meropenem; piperacillin; tazobactam;

Full Text:

pdf


References

  1. Su SC, Mario V, Lenie D, Yu FW, Ya LC, Tsung CC. Identification of non-fermenting Gram-negative bacteria of clinical importance by an oligonucleotide array. J Med Microbiol 2009; 58: 596-605. http://doi.org/10.1099/jmm.0.004606-0
  2. Pradipta IS, Sandiana AT, Halimah E, Diantini A, Lestari K, Abdulah R. Microbial and resistance profile in isolate from adult sepsis patients: An observational study at an Indonesian private hospital during 2009-2012. Int J Pharm Sci Rev Res 2013;19 (2): 24–9.
  3. Viswanathan R, Singh AK, Basu S, Chatterjee S, Roy S, Isaacs D. Multidrug-resistant, non-fermenting, Gram-negative bacilli in neonatal sepsis in Kolkata, India: a 4-year study. Paediatr Int Child Health 2013; 34(1): 56-9. https://doi.org/10.1179/2046905513Y.0000000072
  4. Howland RD, Mycek MJ, Harvey RA, Champe PC. Lippincott’s Illustrated Reviews: Pharmacology 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2005.
  5. Young Paul. Intensive Care Unit Drug Manual, 2nd ed. Wellington: Wellington Regional Hospital, 2013.
  6. Ciptaningtyas, VR. Antibiotik untuk Mahasiswa Kedokteran. Yogyakarta: Graha Ilmu, 2014.
  7. Joly-Guillou ML, Kempf M, Cavallo JD, Chomarat M, Dubreuil L, Maugein J, et al. Comparative in vitro activity of meropenem, imipenem and piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study. BMC Infectious Diseases, 2010; 10(72): 1-9.
  8. White RL, Burgess DS, Manduru M, Bosso JA. Comparison of three different in vitro methods of detecting synergy : time-kill, checkerboard, and E test. Antimicrob Agent Chemother 1996;40 (8):1914-18.
  9. Bergogne-Berezin E, Friedman H, Bendinelli M. Acinetobacter: biology and pathogenesis. In: Friedman H, Bendinelli M series editors, Infectious Agents and Pathogenesis. New York: Springer Science, 2008.
  10. Liofilchem. MIC test strip preliminary guide. 2015; 1–20.
  11. Harris P, Peleg AY, Iredell J, Ingram PR, Miyakis S, Stewardson AJ, et al. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial. Trials 2015; 16:24. http://doi.org/ 10.1186/s13063-014-0541-9
  12. Byarugaba DK. Mechanism of antimicrobial resistance. In: de J Sosa A, Byarugaba DK, Hsueh PR, Kariuki S, Okeke IR editors. Antimicrobial Resistance in Develoving Countries. New York: Springer, 2010. pp. 15-26.
  13. Byrugaba D. A view on antimicrobial resistance in developing countries and responsible risk factors. Int J Antimicrob Agents 2004; 24(2):105-10.
  14. Dewi R. Sepsis pada anak : pola kuman dan uji kepekaan. Majalah Kedokteran Indonesia 2010; 61: 101–6.
  15. Bollenbach T. Antimicrobial interactions: mechanism and implication for drug discovery and resistance evolution. Curr Op Microbiol 2015; 27: 1-9. http://doi.org/10.1016/j.mib.2015.05.008



DOI: https://doi.org/10.19106/JMedSci005201202001

Article Metrics

Abstract views : 1907 | views : 1991


Bookmark and Share


Copyright (c) 2020 Alindya Diani, Eggi Arguni, Ludhang Pradipta Rizki

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.